Skip to main content
. 2006 Apr 24;103(18):7154–7158. doi: 10.1073/pnas.0510320103

Fig. 2.

Fig. 2.

Effect of the Y5R antagonist on fat weight and plasma glucose and insulin levels. (A) Mesenteric fat weight. (B) Plasma glucose levels. (C) Plasma insulin levels. Data are expressed as means ± SE (n = 8–9). ∗, P < 0.05 (compared with vehicle).